Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

Kathryn L. Pepple; Phoebe Lin

doi:10.1016/j.ophtha.2018.05.014

Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

Kathryn L. Pepple, Phoebe Lin

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

Original language	English (US)
Pages (from-to)	1977-1983
Number of pages	7
Journal	Ophthalmology
Volume	125
Issue number	12
DOIs	https://doi.org/10.1016/j.ophtha.2018.05.014
State	Published - Dec 2018

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2018.05.014

Cite this

@article{14dbe34c56574bc2a233807443d99f60,

title = "Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis",

abstract = "The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.",

author = "Pepple, {Kathryn L.} and Phoebe Lin",

note = "Publisher Copyright: {\textcopyright} 2018 American Academy of Ophthalmology",

year = "2018",

month = dec,

doi = "10.1016/j.ophtha.2018.05.014",

language = "English (US)",

volume = "125",

pages = "1977--1983",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

AU - Pepple, Kathryn L.

AU - Lin, Phoebe

PY - 2018/12

Y1 - 2018/12

N2 - The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

AB - The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

UR - http://www.scopus.com/inward/record.url?scp=85049355381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049355381&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2018.05.014

DO - 10.1016/j.ophtha.2018.05.014

M3 - Review article

C2 - 30458922

AN - SCOPUS:85049355381

SN - 0161-6420

VL - 125

SP - 1977

EP - 1983

JO - Ophthalmology

JF - Ophthalmology

IS - 12

ER -

Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this